Analysis of KRAS , NRAS , BRAF , PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Analysis of
KRAS
,
NRAS
,
BRAF
,
PIK3CA
and
TP53
mutations in a large prospective series of locally advanced rectal cancer patients
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CANCER
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-06-14
DOI
10.1002/ijc.32507
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2018) R Glynne-Jones et al. ANNALS OF ONCOLOGY
- Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study
- (2018) Maxime J M van der Valk et al. LANCET
- KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer
- (2018) Francesco Sclafani et al. Scientific Reports
- Non-V600BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer
- (2017) Jeremy C. Jones et al. JOURNAL OF CLINICAL ONCOLOGY
- PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer
- (2016) F. Sclafani et al. ANNALS OF ONCOLOGY
- KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy
- (2016) Oliver S. Chow et al. ANNALS OF SURGICAL ONCOLOGY
- Prognostic Value ofBRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer
- (2016) Julien Taieb et al. JNCI-Journal of the National Cancer Institute
- Integrated Multiregional Analysis Proposing a New Model of Colorectal Cancer Evolution
- (2016) Ryutaro Uchi et al. PLoS Genetics
- Prognostic Value ofBRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer
- (2016) Julien Taieb et al. JNCI-Journal of the National Cancer Institute
- Heterogeneity of KRAS Mutation Status in Rectal Cancer
- (2016) Peter Jo et al. PLoS One
- BRAFcodons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis
- (2015) C. Cremolini et al. ANNALS OF ONCOLOGY
- Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance)
- (2015) F. A. Sinicrope et al. CLINICAL CANCER RESEARCH
- A Big Bang model of human colorectal tumor growth
- (2015) Andrea Sottoriva et al. NATURE GENETICS
- Fc RIIa and Fc RIIIa Polymorphisms and Cetuximab Benefit in the Microscopic Disease
- (2014) F. Sclafani et al. CLINICAL CANCER RESEARCH
- RAS mutations and cetuximab in locally advanced rectal cancer: Results of the EXPERT-C trial
- (2014) F. Sclafani et al. EUROPEAN JOURNAL OF CANCER
- Neoadjuvant Chemotherapy Without Routine Use of Radiation Therapy for Patients With Locally Advanced Rectal Cancer: A Pilot Trial
- (2014) Deborah Schrag et al. JOURNAL OF CLINICAL ONCOLOGY
- TP53 Mutational Status and Cetuximab Benefit in Rectal Cancer: 5-Year Results of the EXPERT-C Trial
- (2014) Francesco Sclafani et al. JNCI-Journal of the National Cancer Institute
- Mutations in Specific Codons of the KRAS Oncogene are Associated with Variable Resistance to Neoadjuvant Chemoradiation Therapy in Patients with Rectal Adenocarcinoma
- (2013) Marjun P. Duldulao et al. ANNALS OF SURGICAL ONCOLOGY
- Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery
- (2013) Olfa Derbel et al. BMC CANCER
- Modern multidisciplinary treatment of rectal cancer based on staging with magnetic resonance imaging leads to excellent local control, but distant control remains a challenge
- (2013) S.M.E. Engelen et al. EUROPEAN JOURNAL OF CANCER
- KRASmutations andCDKN2Apromoter methylation show an interactive adverse effect on survival and predict recurrence of rectal cancer
- (2013) Maija R. J. Kohonen-Corish et al. INTERNATIONAL JOURNAL OF CANCER
- Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy
- (2013) Frank A. Sinicrope et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter Randomized Phase II Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy With or Without Cetuximab Followed by Total Mesorectal Excision in Patients With High-Risk Rectal Cancer (EXPERT-C)
- (2012) Alice Dewdney et al. JOURNAL OF CLINICAL ONCOLOGY
- KRAS genotyping in rectal adenocarcinoma specimens with low tumor cellularity after neoadjuvant treatment
- (2012) Florence Boissière-Michot et al. MODERN PATHOLOGY
- P53 Status as a Predictive Biomarker for Patients Receiving Neoadjuvant Radiation-Based Treatment: A Meta-Analysis in Rectal Cancer
- (2012) Min-Bin Chen et al. PLoS One
- Does Neoadjuvant Therapy Alter KRAS and/or MSI Results in Rectal Adenocarcinoma Testing?
- (2011) Sarah L. Ondrejka et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Identification of a Biomarker Profile Associated With Resistance to Neoadjuvant Chemoradiation Therapy in Rectal Cancer
- (2011) Julio Garcia-Aguilar et al. ANNALS OF SURGERY
- Preoperative High-resolution Magnetic Resonance Imaging Can Identify Good Prognosis Stage I, II, and III Rectal Cancer Best Managed by Surgery Alone
- (2011) Fiona G.M Taylor et al. ANNALS OF SURGERY
- Value of Mismatch Repair, KRAS, and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer
- (2011) Gordon Hutchins et al. JOURNAL OF CLINICAL ONCOLOGY
- Magnetic Resonance Imaging–Detected Tumor Response for Locally Advanced Rectal Cancer Predicts Survival Outcomes: MERCURY Experience
- (2011) Uday B. Patel et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Diagnosis of Response to Neoadjuvant Chemoradiation Therapy in Patients with Locally Advanced Rectal Cancer
- (2011) Zhenbin Chen et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy
- (2011) Janine M Davies et al. Radiation Oncology
- Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy
- (2010) C Bengala et al. BRITISH JOURNAL OF CANCER
- Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial
- (2010) Yu Jo Chua et al. LANCET ONCOLOGY
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- PIK3CA Mutations Predict Local Recurrences in Rectal Cancer Patients
- (2009) Y. He et al. CLINICAL CANCER RESEARCH
- Molecular Genetic Changes Associated With Colorectal Carcinogenesis Are Not Prognostic for Tumor Regression Following Preoperative Chemoradiation of Rectal Carcinoma
- (2009) N. Peter Zauber et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
- (2009) Arnaud D. Roth et al. JOURNAL OF CLINICAL ONCOLOGY
- KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy
- (2009) Jochen Gaedcke et al. RADIOTHERAPY AND ONCOLOGY
- The ‘good’, the ‘bad’, and the ‘ugly’ rectal cancers
- (2007) Lennart Blomqvist et al. ACTA ONCOLOGICA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now